Can-Fite BioPharma (NYSE:CANF) Shares Down 3.1% – What’s Next?

Can-Fite BioPharma Ltd. (NYSE:CANF) fell 3.1% on Tuesday . The company traded as low as $0.3098 and last traded at $0.3170. 797,662 shares changed hands during mid-day trading, a decline of 57% from the average session volume of 1,857,222 shares. The stock had previously closed at $0.3270.

Analyst Upgrades and Downgrades

CANF has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price target on shares of Can-Fite BioPharma in a research report on Tuesday, November 4th. Zacks Research upgraded Can-Fite BioPharma to a “hold” rating in a research note on Thursday, November 6th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $11.00 target price on shares of Can-Fite BioPharma in a research report on Tuesday, November 18th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.75.

Can-Fite BioPharma Stock Down 3.1%

The firm has a 50 day moving average of $0.44 and a 200 day moving average of $0.71. The firm has a market cap of $8.30 million, a PE ratio of -0.18 and a beta of 0.98.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers grew its holdings in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 42.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,268 shares of the company’s stock after purchasing an additional 11,388 shares during the quarter. Rhumbline Advisers owned about 1.08% of Can-Fite BioPharma worth $57,000 at the end of the most recent reporting period. 21.00% of the stock is owned by institutional investors.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.